Barclays
DRUG

Barclays’s Bright Minds Biosciences DRUG Stock Holding History

Barclays’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Buy
3,256
+179
+6% +$14.1K ﹤0.01% 3623
2026
Q1 		$225K Sell
3,077
-6,583
-68% -$530K ﹤0.01% 3618
2025
Q4 		$754K Buy
9,660
+3,079
+47% +$206K ﹤0.01% 3621
2025
Q3 		$399K Sell
6,581
-1,812
-22% -$70.3K ﹤0.01% 3943
2025
Q2 		$219K Buy
+8,393
New +$252K ﹤0.01% 4215

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Barclays's DRUG Position: Q2 2026 in Review

Barclays increased its Bright Minds Biosciences (DRUG) stake by 5.8% in Q2 2026, buying an estimated $14.1K and bringing the position to 3,256 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

Barclays first reported a position in DRUG in Q2 2025 and has held it in 5 quarters since. The position peaked at $754K in Q4 2025. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Barclays held 3,256 shares of Bright Minds Biosciences worth $229K as of Q2 2026.
  • Barclays bought 179 Bright Minds Biosciences shares in Q2 2026, an estimated $14.1K.
  • Bright Minds Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3623 holding.
  • Barclays first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Bright Minds Biosciences position peaked at $754K in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.